Glaxo Faces Another Antitrust Suit Over Relafen Patent

Law360, New York (October 1, 2004, 12:00 AM EDT) -- GlaxoSmithKline, which already has agreed to pay over $250 million to settle charges it broke antitrust law by trying to block generic competition for the arthritis drug Relafen, is facing accusations of antitrust violations and patent gaming in yet another complaint.

In May, the U.K. drug maker agreed to pay $75 million to settle a consumer class action lawsuit brought by advocacy groups that claimed Glaxo falsely obtained a patent for the drug by intentionally failing to disclose an earlier publication that identified the compound used...
To view the full article, register now.